SCHEMBL17079278

SCHEMBL17079278

CC(Cl)c1nnc(CCNC(=O)OCc2ccccc2)s1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.52
LMNA P02545 2/20 0.48
HTT P42858 1/20 0.46
GLS O94925 2/20 0.46
ATM Q13315 1/20 0.45
L3MBTL1 Q9Y468 2/20 0.44
IDO1 P14902 1/20 0.43
MAPT P10636 1/20 0.43
KEAP1 Q14145 1/20 0.43
NFE2L2 Q16236 1/20 0.43
KAT2B Q92831 1/20 0.43
SLC1A3 P43003 1/20 0.42
SLC1A1 P43005 1/20 0.42
KDM4E B2RXH2 1/20 0.42
USP2 O75604 1/20 0.42
HPGD P15428 1/20 0.42
HSD17B10 Q99714 1/20 0.42
TGM2 P21980 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17079276 0.88 SMN1; SMN2 (0.51) SMN1; SMN2LMNAHTTGLSATM
SCHEMBL17079464 0.76 ATM (0.56) SMN1; SMN2LMNAHTTATML3MBTL1
Benzyl Phenethylcarbamate SCHEMBL4287199 0.73 LMNA (0.73) SMN1; SMN2LMNAHTTL3MBTL1IDO1
SCHEMBL6748749 0.73 SMN1; SMN2 (0.63) SMN1; SMN2LMNAHTTL3MBTL1IDO1
SCHEMBL19936423 0.72 LMNA (0.61) SMN1; SMN2LMNAHTTL3MBTL1MAPT
SCHEMBL13055383 0.72 LMNA (0.80) SMN1; SMN2LMNAHTTL3MBTL1IDO1
SCHEMBL7378562 0.71 LMNA (0.65) SMN1; SMN2LMNAHTTL3MBTL1MAPT
SCHEMBL8587051 0.71 LMNA (0.68) SMN1; SMN2LMNAHTTATML3MBTL1
SCHEMBL4043365 0.70 LMNA (0.50) SMN1; SMN2LMNAHTTATML3MBTL1
SCHEMBL22075838 0.70 MAPK1 (0.53) SMN1; SMN2LMNAHTTATML3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9790219-B2 Compounds, compositions, and methods for increasing CFTR activity PROTEOSTASIS THERAPEUTICS, INC. (US) 2017-10-17 US disclosed
US-9790219-B2 Compounds, compositions, and methods for increasing CFTR activity PROTEOSTASIS THERAPEUTICS, INC. (US) 2017-10-17 US disclosed
EP-3116501-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY Proteostasis Therapeutics, Inc. (US) 2017-01-18 EP disclosed
US-20170001993-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY PROTEOSTASIS THERAPEUTICS, INC. 2017-01-05 US disclosed
US-20170001993-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY PROTEOSTASIS THERAPEUTICS, INC. 2017-01-05 US disclosed
WO-2015138909-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY PROTEOSTASIS THERAPEUTICS, INC. (US) 2015-09-17 WO disclosed
WO-2015138909-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY PROTEOSTASIS THERAPEUTICS, INC. (US) 2015-09-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170001993-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY CFTR, ABCB4, KEAP1 SMN1; SMN2 1990/4885LMNA 2143/4885HTT 261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.